Target intelligence / Profile preview

GCOM1 combined protein 1 (GCOM1)

Target
GCOM1
Molecular classification
Other, gene fusion/protein complex, component of transcription machinery, protein-protein interaction partner
01

Overview

GCOM1 combined protein 1 (GCOM1) is a unique, complex gene product resulting from *readthrough transcription across the MYZAP and POLR2M genes* on chromosome 15, generating a protein with domains from both parent loci as well as unique exons[1][3][2]. GCOM1 proteins are expressed predominantly in the **central nervous system** and at the **intercalated disks of cardiomyocytes**, where they participate in **transcription elongation** (by interacting with the RNA polymerase II complex), **cell–cell adhesion** in the heart, and possibly the modulation of NMDA receptor (NMDAR) function in the brain[1][3]. GCOM1 variants that result in loss of function have been directly implicated in **familial dilated and hypertrophic cardiomyopathy**[3]. Experimental evidence suggests a possible role in **neuroprotection** by modulating NMDA receptor–mediated calcium influx, but the exact CNS function is still not fully characterized[1]. No drugs are currently known to target GCOM1 directly, and its major therapeutic potential is as a modulator within protein complexes—especially those relevant to heart and brain pathology. Key evidence: - GCOM1 is the gene product of a complex transcription unit encompassing exons from MYZAP and POLR2M, producing unique proteins not found in either parent gene alone[2][3]. - GCOM1 interacts with cardiac and neuronal proteins, including the NR1 subunit of the NMDA receptor, and is implicated in both cardiac structural integrity and possible neuroprotective pathways[1]. - Homozygous GCOM1 truncating mutations cause familial cardiomyopathy; there are suggested implications for neuropsychiatric and neurodegenerative diseases, but direct clinical links are not fully established[3][1]. No pharmacologic agents are currently known to act on GCOM1 or its protein products[1][3]. Pathogenic GCOM1 variants serve as potential genetic biomarkers in hereditary cardiomyopathy assessment[3].

Other names
FLJ30973GRINL1AMYZAP-POLR2MMYZAP-POLR2M readthroughGcom2MYZAPGRINL1A combined proteinDNA-directed RNA polymerase II subunit GRINL1ADNA-directed RNA polymerase II subunit MGRINL1A combined protein Gcom12GRINL1A complex locus 1Glutamate receptor-like protein 1ANMDAR1 subunit-interacting proteinglutamate receptor, ionotropic, N-methyl D-aspartate-like 1A combined proteinmyocardial zonula adherens protein
02

Mechanism of action

none known (neither direct pharmacologic agents nor established inhibitors/agonists are documented)

03

Biological functions

Transcription elongationgene expression regulationcell–cell adhesioncardiac intercalated disk structuremodulator of NMDA receptor signalingneuroprotection
04

Disease associations

Cardiomyopathy (dilated and hypertrophic forms)neurodegenerative disease (implicated)neuropsychiatric disease (potential/implicated)other cardiac diseases
05

Safety considerations

Loss of function variants associated with familial cardiomyopathy[3]unknown neuropsychiatric or neurodevelopmental risks if disrupted in the CNS
06

Interacting drugs

none known
07

Biomarkers

pathogenic variants are potential genetic biomarkers for familial cardiomyopathy[3]

Beyond the preview

Go deeper on GCOM1 combined protein 1 (GCOM1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on GCOM1 combined protein 1 (GCOM1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call